From our partners at i2i Marketing Group, LLC Dear Investor, Every so often, a micro-cap stock makes a move that shifts it from under the radar to front of the line. That's exactly what just happened here. With the acquisition of a Phase 2-ready drug portfolio, this small biotech has gone from a single-asset story to a diversified pipeline company in a $38 billion global market. Why it matters: - Acquisition adds both IV and oral anticoagulant candidates
- Lead program already carries Fast Track & Orphan Drug designations
- Focused on patients Big Pharma has ignored - massive unmet need
- Partnerships already in play with major names
- Lean balance sheet, multiple shots on goal, and a category-leadership strategy
Micro-cap opportunities like this don't stay quiet for long. That's why it's #1 on our watchlist right now. View Ticker & Full Report | 
0 Response to "Micro-Cap Biotech Snaps Up Phase 2 Drug Portfolio - Now a Diversified Play"
Post a Comment